Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Consortium

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

MSD’s Kate Tillett rewarded for healthcare comms excellence

Company's external affairs director wins at Communiqué 2014

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

Grunenthal to market MSD’s pain drug

Acquires rights to Arcoxia in several European countries

- PMLiVE

Interview: Bruno Strigini, MSD

MSD’s president, Europe and Canada, on how pharma is adapting to the market’s new reality

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links